Sequenom, Trovagene deal

TrovaGene (formerly Xenomics Inc.) said a 2008 deal that gave Sequenom rights to TrovaGene's transrenal technology was terminated. TrovaGene regains rights to patents covering transrenal fetal nucleic acids found in maternal urine for noninvasive prenatal and cancer diagnostics. Sequenom said it returned the rights because it could not make commercial use of the technology. TrovaGene added that it is in partnering discussions for the technology. Details were not disclosed. ...